Dashboard
Manage Tickers

LXEO Lexeo Therapeutics, Inc.

Nasdaq www.lexeotx.com


$ 8.42 $ 0.22 (2.68 %)    

Thursday, 06-Nov-2025 15:59:48 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 613.21 $ -11.61 (-1.86 %)
DIA $ 469.77 $ -3.83 (-0.81 %)
SPY $ 671.88 $ -7.27 (-1.07 %)
TLT $ 89.70 $ 0.80 (0.9 %)
GLD $ 366.55 $ -0.44 (-0.12 %)
$ 8.42
$ 8.22
$ 8.05 x 58
$ 8.42 x 15
$ 8.20 - $ 8.62
$ 1.45 - $ 11.72
1,449,778
na
614.55M
$ 2.33
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-05-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-12-2025 03-31-2025 10-Q
4 03-24-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-12-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-11-2024 12-31-2023 10-K
9 12-11-2023 09-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

chardan-capital-maintains-buy-on-lexeo-therapeutics-maintains-17-price-target
Chardan Capital Maintains Buy on Lexeo The...
11/06/2025 00:18:09

Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $17 price target.

lexeo-therapeutics-q3-eps-033-beats-054-estimate
Lexeo Therapeutics Q3 EPS $(0.33) Beats $(...
11/05/2025 12:37:55

Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(...

hc-wainwright--co-maintains-buy-on-lexeo-therapeutics-lowers-price-target-to-13
HC Wainwright & Co. Maintains Buy on Lexeo...
10/21/2025 11:11:48

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and lowers the pric...

reported-earlier-lexeo-therapeutics-prices-135m-public-offering-of-15625m-shares-at-8-per-share-and-125m-warrants-at-79999-each
Reported Earlier, Lexeo Therapeutics Price...
10/17/2025 05:50:33

lexeo-therapeutics-announces-proposed-public-offering-terms-not-disclosed
Lexeo Therapeutics Announces Proposed Publ...
10/16/2025 20:21:40

SEC

guggenheim-initiates-coverage-on-lexeo-therapeutics-with-buy-rating-announces-price-target-of-30
Guggenheim Initiates Coverage On Lexeo The...
10/15/2025 14:26:23

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Lexeo Therapeutics (NASDAQ:LXEO) with a Buy rating and announc...

chardan-capital-maintains-buy-on-lexeo-therapeutics-raises-price-target-to-17
Chardan Capital Maintains Buy on Lexeo The...
10/07/2025 17:56:51

Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and raises the price target fr...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/07/2025 17:06:17

james-hardie-industries-amd-trilogy-metals-btq-technologies-and-other-big-stocks-moving-higher-on-tuesday
James Hardie Industries, AMD, Trilogy Meta...
10/07/2025 14:57:02

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/07/2025 12:08:21

lexeo-therapeutics-fda-feedback-opens-faster-path-pivotal-study-for-friedreich-ataxia-gene-therapy-could-shrink-and-speed-up-approval
Lexeo Therapeutics, FDA Feedback Opens Fas...
10/07/2025 10:04:55

Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for ...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
09/24/2025 17:06:12

fda-outlines-process-to-speed-up-rare-disease-therapy-approvals
FDA Outlines Process To Speed Up Rare Dise...
09/04/2025 18:50:03

FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questi...

hc-wainwright--co-maintains-buy-on-lexeo-therapeutics-lowers-price-target-to-9
HC Wainwright & Co. Maintains Buy on Lexeo...
08/15/2025 11:27:11

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and lowers the pric...

lexeo-therapeutics-appoints-louis-tamayo-as-cfo-succeeding-kyle-rasbach
Lexeo Therapeutics Appoints Louis Tamayo A...
08/14/2025 11:54:52

lexeo-therapeutics-q2-eps-060-beats-068-estimate
Lexeo Therapeutics Q2 EPS $(0.60) Beats $(...
08/14/2025 11:44:19

Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.60) per share which beat the analyst consensus estimate of $(...

this-lexeo-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-thursday
This Lexeo Therapeutics Analyst Begins Cov...
07/31/2025 16:11:53

oppenheimer-initiates-coverage-on-lexeo-therapeutics-with-outperform-rating-announces-price-target-of-20
Oppenheimer Initiates Coverage On Lexeo Th...
07/31/2025 12:06:27

Oppenheimer analyst Leland Gershell initiates coverage on Lexeo Therapeutics (NASDAQ:LXEO) with a Outperform rating and anno...

the-fda-grants-breakthrough-therapy-designation-to-lexeo-therapeutics-lx2006-based-on-clinical-evidence-generated-on-both-cardiac-and-neurologic-measures-of-friedreich-ataxia
The FDA Grants Breakthrough Therapy Design...
07/07/2025 11:06:38

LX2006 has also been selected to participate in the FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot ...

1-lexeo-launches-40m-rna-heart-drug-venture-with-backing-from-top-biotech-investors
1. Lexeo Launches $40M RNA Heart Drug Vent...
06/24/2025 11:33:13

Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION